AC/SAS:gth 02/28/06 4239-66649-03 491972 E-323-2003/0-US-03

EXPRESS MAIL LABEL NO. EV669611737US
DATE OF DEPOSIT: February 28, 2006

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | |
|---|---|---|
| | Attorney Docket Number | 4239-66649-03 |
| | Application Number | 10570220 |
| | Filing Date | Herewith |
| | First Named Inventor | Kashmiri |
| | Art Unit | |
| | Examiner Name | |

## U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number | Publication Date | Name of Applicant or Patentee |
|---|---|---|---|---|
| | | 4,816,567 | 28 March 1989 | Cabilly *et al.* |
| | | 5,472,693 | 5 Dec 1995 | Gourlie *et al.* |
| | | 5,482,040 | 9 Jan 1996 | Martin, Jr. |
| | | 5,512,443 | 30 April 1996 | Schlom *et al.* |
| | | 5,534,254 | 9 July 1996 | Huston *et al.* |
| | | 5,585,089 | 17 Dec 1996 | Queen *et al.* |
| | | 5,688,657 | 18 Nov 1997 | Tsang *et al.* |
| | | 5,976,531 | 2 Nov 1999 | Mezes *et al.* |
| | | 5,976,845 | 2 Nov 1999 | Mezes *et al.* |
| | | 5,994,511 | 30 Nov 1999 | Lowman *et al.* |
| | | 6,054,297 | 25 April 2000 | Carter *et al.* |
| | | 6,180,370 | 30 Jan 2001 | Queen *et al.* |
| | | 6,333,405 | 25 Dec 2001 | Anderson *et al.* |
| | | 6,495,137 | 17 Dec 2002 | Mezes *et al* |

| EXAMINER SIGNATURE: | DATE CONSIDERED: |
|---|---|

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

AC/SAS:gth 02/28/06 4239-66649-03 491972 E-323-2003/0-US-03

EXPRESS MAIL LABEL NO. EV669611737US
DATE OF DEPOSIT: February 28, 2006

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | |
|---|---|---|
| | Attorney Docket Number | 4239-66649-03 |
| | Application Number | |
| | Filing Date | Herewith |
| | First Named Inventor | Kashmiri |
| | Art Unit | |
| | Examiner Name | |

**FOREIGN PATENT DOCUMENTS**

| Examiner's Initials* | Cite No. (optional) | Country | Number | Publication Date | Name of Applicant or Patentee |
|---|---|---|---|---|---|
| | | Canada | 2,068,593 | 8 July 2003 | Mark *et al.* |
| | | Canada | 2,131,355 | 2 March 1996 | Shu *et al.* |
| | | EPC | EP0239400 | 30 Sep 1987 | Winter, G. |
| | | EPC | EP0365997 | 2 May 1990 | Mezes *et al.* |
| | | WIPO/PCT | WO 89/00692 | 26 Jan 1989 | Schlom *et al.* |
| | | WIPO/PCT | WO 89/01783 | 9 March 1989 | Bodmer *et al.* |
| | | WIPO/PCT | WO 90/04410 | 3 May 1990 | Mezes *et al.* |
| | | WIPO/PCT | WO 91/00295 | 10 Jan 1991 | Hellstrom *et al.* |
| | | WIPO/PCT | WO 93/12231 | 24 June 1993 | Mezes *et al.* |
| | | WIPO/PCT | WO 96/13594 | 9 May 1996 | Pastan *et al.* |
| | | WIPO/PCT | WO 97/26010 | 24 July 1997 | Blackburn *et al.* |
| | | WIPO/PCT | WO 98/18809 | 7 May 1998 | Greenburg *et al.* |
| | | WIPO/PCT | WO 99/43816 | 2 Sep 1999 | Anderson *et al.* |
| | | WIPO/PCT | WO 00/26394 | 11 May 2000 | Kashmiri *et al.* |
| | | WIPO/PCT | WO 04/003155 | 8 January 2004 | Kashmiri *et al.* |

| EXAMINER SIGNATURE: | DATE CONSIDERED: |
|---|---|

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

AC/SAS:gth 02/28/06 4239-66649-03 491972 E-323-2003/0-US-03

EXPRESS MAIL LABEL NO. EV669611737US
DATE OF DEPOSIT: February 28, 2006

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | |
|---|---|---|
| | Attorney Docket Number | 4239-66649-03 |
| | Application Number | 10/570220 |
| | Filing Date | Herewith |
| | First Named Inventor | Kashmiri |
| | Art Unit | |
| | Examiner Name | |

| Examiner's Initials* | Cite No. (optional) | OTHER DOCUMENTS |
|---|---|---|
| | | ABERGEL *et al.*, "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab'," *Proteins: Structure, Function, and Genetics* 17:438-443, 1993. |
| | | BERZOFSKY *et al.*, p. 242, *Fundamental Immunology*, Paul (Ed.) Raven Press, NY, 1993 |
| | | COLCHER *et al.*, "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies," *Cancer Research* 48:4597-4603, 1988. |
| | | De PASCALIS *et al.*, "Generation of minimally immunogenic high affinity variants of humanized anti-carcinoma antibody HuCC49V10 by in vitro affinity maturation," *Proceedings of the American Association for Cancer Research*, 44(2):1115-1116, 2003. |
| | | De PASCALIS *et al.*, "*In Vitro* Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants," *Clinical Cancer Research*, 9:5521-5531, 2003. |
| | | DIVGI *et al.*, "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen," *Nucl. Med. Biol.* 21(1):9-15, 1994. |
| | | GONZALES *et al.*, "Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues," *Molecular Immunology*, 40(6):337-349, 2003. |
| | | GONZALES *et al.*, "Reducing the potential immunogenicity of humanized CC49 by genetic manipulation of framework residues," *Proceedings of the American Association for Cancer Research*, 44:1118, 2003. |
| | | HAKIMI *et al.*, "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys," *J. Immunol.* 147:1352-1359, 1991. |
| | | HAND *et al.*, "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma," *Cancer Supplement* 73(3):1105-1113, 1994. |
| | | IWAHASHI *et al.*, "CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity," *Molecular Immunology* 36:1079-1091, 1999. |
| | | JOHNSON *et al.*, "Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3," *Cancer Research* 46:850-857, 1986. |
| | | JONES *et al.*, "Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse," *Nature* 321:522-525, 1986. |

| EXAMINER SIGNATURE: | DATE CONSIDERED: |
|---|---|

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | |
|---|---|---|
| | Attorney Docket Number | 4239-66649-03 |
| | Application Number | |
| | Filing Date | Herewith |
| | First Named Inventor | Kashmiri |
| | Art Unit | |
| | Examiner Name | |

| Examiner's Initials* | Cite No. (optional) | OTHER DOCUMENTS |
|---|---|---|
| | | KASHMIRI *et al.*, Chapter 21 in *Methods in Molecular Biology, Vol. 248: Antibody Engineering: Methods and Protocols*, p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003 |
| | | KASHMIRI *et al.*, "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," *Crit. Rev. Oncol. Hematol.* 38:3-16, 2001. |
| | | KASHMIRI *et al*, "Generation, Characterization, and *in Vivo* Studies of Humanized Anticarcinoma Antibody CC49," *Hybridoma* 14(5):461-473, 1995. |
| | | KASHMIRI *et al.*, "SDR grafting – a new approach to antibody humanization," *Methods*, 36:25-34, 2005 |
| | | MULLIGAN *et al.*, "Phase I Study of Intravenous $^{177}$Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma," *Clinical Cancer Research* 1:1447-1454, 1995. |
| | | MURARO *et al.*, "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," *Cancer Research* 48:4588-4596, 1988. |
| | | PADLAN, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties," *Molecular Immunology* 28(4/5):489-498, 1991. |
| | | PADLAN, "Anatomy of the antibody molecule," *Mol. Immunol.* 31:169-217, 1994. |
| | | PADLAN *et al.*, "Identification of Specificity-determining Residues in Antibodies," *The FASEB Journal* 9:133-139, 1995. |
| | | RIECHMAN *et al.*, "Reshaping human antibodies for therapy," *Nature (London)* 332:323-327, 1988. |
| | | RIXON *et al.*, "Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies," *The Journal of Immunology* 151(11):6559-6568, 1993. |
| | | RUDIKOFF *et al.*, "Single amino acid substitution altering antigen-binding specificity," *PNAS* 79(6):1979-1983, 1982 |
| | | SALDANHA *et al.*, "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," *Mol. Immunol.* 36:709-719, 1999. |

| EXAMINER SIGNATURE: | DATE CONSIDERED: |
|---|---|

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

AC/SAS:gth 02/28/06 4239-66649-03 491972 E-323-2003/0-US-03

EXPRESS MAIL LABEL NO. EV669611737US
DATE OF DEPOSIT: February 28, 2006

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | |
|---|---|---|
| | Attorney Docket Number | 4239-66649-03 |
| | Application Number | 10570220 |
| | Filing Date | Herewith |
| | First Named Inventor | Kashmiri |
| | Art Unit | |
| | Examiner Name | |

| | | |
|---|---|---|
| | | SCHIER *et al.*, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," *J. Mol. Biol.* 263:551-567, 1996. |
| | | SHA *et al.*, "A Heavy-chain Grafted Antibody that Recognizes the Tumor-associated TAG72 Antigen," *Cancer Biotherapy* 9(4):341-349, 1994. |
| | | SHARKEY *et al.*, "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," *Cancer Res.* 55:5935s-5945s, 1995. |
| | | SLAVIN-CHIORINI *et al.*, "A CDR-grafted (humanized) domain-deleted antitumor antibody," *Cancer Biother. Radiopharm.* 12:305-316, 1997. |
| | | SLAVIN-CHIORINI *et al.*, "Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins," *Cancer Research (Supplement)* 55:5957s-5967s, 1995. |
| | | TAMURA *et al.*, "Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only," *Journal of Immunology* 164(3):1432-1441, 2000. |
| | | WU *et al.*, "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," *J. Mol. Biol.* 294:151-162, 1999. |
| | | XIANG *et al.*, "The Tyrosine Residue at Position 97 in the $V_H$ CDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen," *Cancer Biotherapy* 8(3):253-262, 1993. |
| | | XIANG *et al.*, "Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction," *Protein Engineering* 9(6):539-543, 1996. |
| | | XIANG *et al.*, "Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding," *Protein Eng.* 12:417-421, 1999. |
| | | International Search Report issued on April 15, 2005, for PCT Patent Application No. PCT/US2004/028004. |

| | |
|---|---|
| EXAMINER SIGNATURE: /David Blanchard/ | DATE CONSIDERED: 08/19/2008 |

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/